［1］Tanaka TI，Alawi F.Human papillomavirus and oropharyngeal cancer［J］.Dent Clin North Am，2018，62(1)：111-120.
［2］Gannon OM,Antonsson A,Bennett IC,et al.Viral infections and breast cancer-A current perspective［J］.Cancer Letters，2018(420)：182-189.
［3］Elamrani A，Gheit T，Benhessou M，et al.Prevalence of mucosal and cutaneous human papillomavirus in Moroccan breast cancer［J］.Papillomavirus Research，2018(5)：150-155.
［4］Amador-Molina A，Trejo-Moreno C，Romero-Rodríguez D，et al.Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8 cytotoxic response and impairs the growth of E1-expressing tumors［J］.Vaccine，2019，37(9)：1219-1228.
［5］Kantang W,Chunstrivirot S，Muangsin N,et al.Design of peptides as inhibitors of human papillomavirus 16 transcriptional regulator E1-E2［J］.Chemical Biology & Drug Design，2016，88(4)：475-484.
［6］Miaomiao Ma，Yaning Feng,Peiwen Fan,et al.Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma［J］.Infectious Agents and Cancer，2018，13(undefined)：35.
［7］Michaelle Chojnacki,Thomas Melendy.The HPV E2 transcriptional transactivation protein stimulates cellular DNA polymerase epsilon［J］.Viruses，2018，10(6)：321.
［8］Zummeren MV,Kremer WW,Leeman A,et al.HPV E4 expression and DNA hypermethylation of CADM1，MAL，and miR124-2 genes in cervical cancer and precursor lesions［J］.Modern Pathology，2018，31(12)：1842-1850.
［9］Stevenson A,Kavanagh K,Pan J,et al.Risk stratification of cervical disease using detection of human papillomavirus (HPV) E4 protein and cellular MCM protein in clinical liquid based cytology samples［J］.Journal of Clinical Virology，2018，108(undefined)：19-25.
［10］Aldo Venuti，Francesca Paolini，Lubna Nasir，et al.Papillomavirus E5：the smallest oncoprotein with many functions［J］.Molecular Cancer，2011，10(undefined)：140.
［11］de Freitas AC,de Oliveira THA,Barros MR Jr，et al.hrHPV E5 oncoprotein：immune evasion and related immunotherapies［J］.Journal of Experimental & Clinical Cancer Research：CR，2017，36(1)：71.
［12］Christopher WW,Ethan LM.Human papillomavirus type 18 E5 oncogene supports cell cycle progression and impairs epithelial differentiation by modulating growth factor receptor signalling during the virus life cycle［J］.Oncotarget，2017，8(61)：103581-103600.
［13］F Belleudi,L Leone,V Purpura，et al.HPV16 E5 affects the KGFR/FGFR2b-mediated epithelial growth through alteration of the receptor expression，signaling and endocytic traffic［J］.Oncogene，2011，30(50)：4963-4976.
［14］Jung-Min Oh，Soo Sam Steve Kim，Eun-Ah Cho,et al.Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells［J］.Carcinogenesis，2010，31(3)：402-410.
［15］ Scott ML，Coleman DT，Kelly KC，et al.Human papillomavirus type 16 E5-mediated upregulation of Met in human keratinocytes［J］.Virology，2018，519(undefined)：1-11.
［16］G Hossein A，Mohammad H，Barbara M，et al.E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain［J］.International Journal of Cancer，2010，119(9)：2105-2112.
［17］Campo MS，Graham SV，Cortese MS，et al.HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells［J］.Virology，2010，407(1)：137-142.
［18］ Estêvo D，Costa NR，Gil da Costa RM，et al.Hallmarks of HPV carcinogenesis：The role of E6，E7 and E5 oncoproteins in cellular malignancy［J］.Biochimica et Biophysica Acta-Gene Regulatory Mechanisms，2019，1862(2)：153-162.
［19］Mcbride AA，Warburton A.The role of integration in oncogenic progression of HPV-associated cancers［J］.Plos Pathogens，2017，13(4)：e1006211.
［20］Network TCGA.Integrated genomic and molecular characterization of cervical cancer［J］.Nature，2017，543(7645)：378-384.
［21］Martinezzapien D，Ruiz FX，Poirson J，et al.Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53［J］.Nature，2016，529(7587)：541-545.
［22］Maria F，Johnson MM，Marnelli B，et al.The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity［J］.Journal of Virology，2007，81(8)：4116-4129.
［23］Xie X，Piao L，Bullock BN，et al.Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma［J］.Oncogene，2014，33(8)：1037-1046.
［24］Chiantore MV，Mangino G，Iuliano M，et al.Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs：additional evidence in HPV-induced tumorigenesis［J］.Journal of Cancer Research & Clinical Oncology，2016，142(8)：1751-1763.
［25］Yue Z，Ying H，Tian T，et al.MiR-21-5p，miR-34a，and human telomerase RNA component as surrogate markers for cervical cancer progression［J］.Pathology-Research and Practice，2018，214(3)：S0344033817310130.
［26］Shah M，Anwar MA，Park S，et al.In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response［J］.Scientific Reports，2015，5(1)：13446.
［27］ Pańczyszyn A，Boniewska-Bernacka E.Telomeres and telomerase during human papillomavirus-induced carcinogenesis［J］.Molecular Diagnosis & Therapy，2018，22(4)：1-10.
［28］Roman A，Munger K.The papillomavirus E7 proteins［J］.Virology，2013，445(1-2)：138-168.
［29］Fischer M，Uxa S，Stanko C，et al.Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway［J］.Scientific Reports，2017，7(1)：2603.
［30］Songock WK，Kim SM，Bodily JM.The human papillomavirus E7 oncoprotein as a regulator of transcription［J］.Virus Research，2017(231)：56-75.
［31］Hu H，Zhao J，Yu W，et al.Human papillomavirus DNA，HPV L1 capsid protein and p16 INK4a protein as markers to predict cervical lesion progression［J］.Archives of Gynecology and Obstetrics，2019，299(1)：141-149.
［32］Zheng L，Yanru WU，Wang Y.Clinical significance of HPV DNA and HPV L1 protein detection in cervical exfoliated cells［J］.China Medical Herald，2016，13(5)：107-110.
［33］Aksoy P，Gottschalk EY，Meneses PI.HPV entry into cells［J］.Mutation Research/Reviews in Mutation Research，2016(772)：13-22.
［34］ Breiner B，Preuss L，Roos N，et al.Refolding and in vitro characterization of human papillomavirus 16 minor capsid protein L2［J］.Biological Chemistry，2019，400(4)：513-522.
［35］Campos SK.Subcellular trafficking of the papillomavirus genome during initial infection：The remarkable abilities of minor capsid protein L2［J］.Viruses，2017，9(12)：370.
［36］Mendoza L，Picconi MA，Mirazo S，et al.Distribution of HPV-16 variants among isolates from Paraguayan women with different grades of cervical lesion［J］.International Journal of Gynaecology & Obstetrics the Official Organ of the International Federation of Gynaecology & Obstetrics，2013，122(1)：44-47.
［37］Mosmann JP，Monetti MS，Frutos MC，et al.Mutation detection of E6 and LCR genes from HPV 16 associated with carcinogenesis［J］.Asian Pac J Cancer Prev，2015，16(3)：1151-1157.
［38］Emiko S，Ferran MC，Baker CC，et al.Repression of HPV16 early region transcription by the E2 protein［J］.Virology，2006，351(1)：29-41.
［39］Shailja P，Neeraj J，Prusty BK，et al.Human papillomavirus type 16 variant analysis of E6，E7，and L1 genes and long control region in biopsy samples from cervical cancer patients in north India［J］.Journal of Clinical Microbiology，2008，46(3)：1060.